Literature DB >> 22682054

Robotic-assisted thymectomy with Da Vinci II versus sternotomy in the surgical treatment of non-thymomatous myasthenia gravis: early results.

S Renaud1, N Santelmo, M Renaud, M-C Fleury, J De Seze, C Tranchant, G Massard.   

Abstract

BACKGROUND: The role of thymectomy in myasthenia gravis remains controversial. The remission rate 5years after surgery varies from 13 to 51% in the literature. Sternotomy is the standard technique, though unacceptable by patients because of significant esthetic sequelae. Our objective was to demonstrate that the robot-assisted technique using the Da Vinci Surgical Robot II is at least as efficient and leaves fewer scars than the standard surgical technique.
METHODS: We retrospectively reviewed the data of 31 consecutive patients suffering from myasthenia gravis who underwent surgery in our center from January 1998 to March 2010. Ten patients with thymoma were excluded from this study. Two groups were formed: group 1 corresponding to patients treated with sternotomy, group 2 patients with robot-assisted technique. The duration of the hospital stay, the pain on D1, the degree of improvement at 1year according to Myasthenia Gravis Foundation of America (MGFA) classification, the frequency of relapses, and perioperative treatment were studied.
RESULTS: Our sample consisted of 14 women and seven men. The mean age was 31.3years. The mean delay before surgery was 24months. Group 1 included 15 patients and group 2 had six patients. The complete remission rate at 1year was 9.5% (n=2). Surgery decreased the frequency of relapses after surgery (P=0.08) equally in the two groups. The duration of hospital stay and the pain level on D1 in group 2 were significantly lower than those in group 1 (P=0.02 and P<0.001). The degree of postoperative improvement was not significantly different between the two groups (P=0.31).
CONCLUSION: The results at 1year are fully comparable for sternotomy and the robot-assisted technique. The robot provides additional benefits of minimally invasive techniques: minimal esthetic sequelae in often young patients, less parietal morbidity (including pain), shorter hospital stays. Our complete remission rate, lower than those in the literature, must be considered taking into account the early nature of these results. The surgical robot, because of its many advantages, appears to be a promising technique and should facilitate the early management of these patients.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22682054     DOI: 10.1016/j.neurol.2012.02.013

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  6 in total

1.  The end of robot-assisted laparoscopy? A critical appraisal of scientific evidence on the use of robot-assisted laparoscopic surgery.

Authors:  Jeroen Heemskerk; Nicole D Bouvy; Cor G M I Baeten
Journal:  Surg Endosc       Date:  2014-04       Impact factor: 4.584

Review 2.  Thymic minimally invasive surgery: state of the art across the world-Europe.

Authors:  José Ramon Matilla; Walter Klepetko; Bernhard Moser
Journal:  J Vis Surg       Date:  2017-05-16

Review 3.  Thymectomy in Myasthenia Gravis: A Narrative Review.

Authors:  Danah Aljaafari; Noman Ishaque
Journal:  Saudi J Med Med Sci       Date:  2022-04-29

Review 4.  A systematic review of robotic versus open and video assisted thoracoscopic surgery (VATS) approaches for thymectomy.

Authors:  Katie E O'Sullivan; Usha S Kreaden; April E Hebert; Donna Eaton; Karen C Redmond
Journal:  Ann Cardiothorac Surg       Date:  2019-03

5.  Robot-assisted thoracic surgery in Colombia: a multi-institutional initial experience.

Authors:  Miguel Ricardo Buitrago; Juliana Restrepo
Journal:  Ann Cardiothorac Surg       Date:  2019-03

Review 6.  Thymectomy via open surgery or robotic video assisted thoracic surgery: Can a recommendation already be made?

Authors:  Judith Buentzel; Carmen Straube; Judith Heinz; Christian Roever; Alexander Beham; Andreas Emmert; Marc Hinterthaner; Bernhard C Danner; Alexander Emmert
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.